GlassScriptPhysician profile
Olivia Hartmann
NPI 1144935081
$1,614.92
in general payments reported to CMS, 2019-2025
28 companies · $652 in 2025
The $652 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $405 · 2024: $558 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,614.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $199.21 | 2023-2025 | Niktimvo, Jakafi, Jakafi |
| Astellas Pharma US INC | $182.07 | 2023-2024 | Cresemba, Xospata |
| Revance Therapeutics, INC. | $142.86 | 2024 | Daxxify |
| Ipsen Biopharmaceuticals, INC | $125.00 | 2024 | Tazverik |
| Abbvie INC. | $112.65 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $88.06 | 2023-2025 | |
| Legend Biotech USA INC. | $84.97 | 2024 | |
| Merck Sharp & Dohme LLC | $71.14 | 2025 | Prevymis, Zerbaxa |
| Takeda Pharmaceuticals U.S.A., INC. | $69.23 | 2023-2025 | Livtencity, Iclusig |
| Sobi, INC | $64.87 | 2024-2025 | |
| Glaxosmithkline, LLC. | $59.27 | 2024-2025 | Ojjaara |
| Genzyme Corporation | $49.30 | 2025 | |
| Pfizer INC. | $38.05 | 2023-2024 | |
| Daiichi Sankyo INC. | $35.38 | 2024-2025 | Vanflyta |
| Celgene Corporation | $34.69 | 2023 | Reblozyl |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $22.91 | 2023 | Adcetris |
| Regeneron Healthcare Solutions, INC. | $22.61 | 2025 | Lynozyfic |
| Genmab U.S., INC. | $22.23 | 2023 | Epkinly |
| Apellis Pharmaceuticals, INC. | $21.10 | 2025 | Empaveli |
| Kyowa Kirin, INC. | $20.79 | 2025 | |
| Servier Pharmaceuticals LLC | $20.51 | 2025 | |
| Janssen Biotech, INC. | $19.81 | 2025 | Carvykti |
| Astrazeneca Pharmaceuticals LP | $19.55 | 2023 | Calquence |
| Pharmacyclics LLC, An Abbvie Company | $19.13 | 2023 | Imbruvica |
| Azurity Pharmaceuticals, INC. | $18.60 | 2025 | Danziten |
| Beone Medicines USA, INC. | $17.92 | 2025 | Brukinsa |
| Lilly USA, LLC | $17.73 | 2025 | Jaypirca |
| Genentech USA, INC. | $15.28 | 2024 | Venclexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Hartmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.